PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532426
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532426
Global RNAi technology market is estimated to be valued at USD 2.70 Bn in 2024 and is expected to reach USD 7.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.8% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 2.70 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 14.80% | 2031 Value Projection: | US$ 7.10 Bn |
Global RNAi technology market growth is driven by growing applications of RNA interference technology in therapeutics development and research. RNA interference or RNAi refers to the process of gene silencing mediated by short interfering RNAs (siRNAs) or microRNAs (miRNAs). It has emerged as a powerful tool for selective inhibition of gene expression and functional genomics screens. RNAi holds immense potential for developing novel therapeutics by silencing specific disease-causing genes. The development of safe and effective delivery systems further contributes to the commercialization of RNAi-based therapies. Significant investments in RNAi research and development from biopharma companies and government organizations are resulting in a strong product pipeline.
Global RNAi technology market growth is driven by increasing applications of RNAi technology for developing treatments across therapeutic areas. Several drug candidates targeting metabolic, cardiovascular and neurodegenerative disorders are currently under clinical trials. The strong product pipeline and entry of novel RNAi drugs are creating high optimism around the therapeutic potential of this technology. However, technical challenges in RNAi delivery and off-target effects can hamper the market growth. Moreover, requirement of high capital investments for building R&D infrastructure and clinical development deters many small companies. Ongoing research on overcoming the delivery challenges through novel delivery systems such as lipid nanoparticles, polymeric nanoparticles and ligand-conjugated molecules can offer market growth opportunities. Promising clinical outcomes of RNAi-based drugs in late-stage trials can offer market growth opportunities.
Detailed Segmentation-